Cargando…

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions

Detalles Bibliográficos
Autores principales:	Khor, Yet H., Farooqi, Malik, Hambly, Nathan, Kolb, Martin, Ryerson, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952865/ https://www.ncbi.nlm.nih.gov/pubmed/35943331 http://dx.doi.org/10.1164/rccm.202205-0910LE

Ejemplares similares

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?
por: Cottin, Vincent, et al.
Publicado: (2022)

Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse
por: Johannson, Kerri A., et al.
Publicado: (2022)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
por: Fisher, J. H., et al.
Publicado: (2019)

Cough in Idiopathic Pulmonary Fibrosis
por: Mann, Jennifer, et al.
Publicado: (2021)

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry
por: Ryerson, Christopher J., et al.
Publicado: (2016)

Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis
por: Lee, Cathryn T., et al.
Publicado: (2022)

Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
por: Rose, Jonathan A., et al.
Publicado: (2022)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

Functional Criteria to Define Progressive Pulmonary Fibrosis: Searching for the Holy Grail
por: Noboa-Sevilla, María, et al.
Publicado: (2022)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Developing a self-management package for pulmonary fibrosis: an international Delphi study
por: Lee, Joanna Y.T., et al.
Publicado: (2022)

Isoniazid and Pulmonary Fibrosis
por: Chung, Chae Uk, et al.
Publicado: (2015)

Managing comorbidities in idiopathic pulmonary fibrosis
por: Fulton, Blair G, et al.
Publicado: (2015)

Definition of Chronic Obstructive Pulmonary Disease: Occupational Environmental Contribution
por: Harber, Philip
Publicado: (2022)

Clinicians’ and Researchers’ Perspectives on a New Chronic Obstructive Pulmonary Disease Exacerbation Definition: Rome Wasn’t Built in a Day
por: Althobiani, Malik A., et al.
Publicado: (2023)

Novel Insight into Pulmonary Fibrosis and Long COVID
por: Kamp, Jan C., et al.
Publicado: (2023)

Chronic Obstructive Pulmonary Disease Definition: Is It Time to Incorporate the Concept of Failure of Lung Regeneration?
por: Confalonieri, Marco, et al.
Publicado: (2022)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
por: Raghu, Ganesh, et al.
Publicado: (2022)

Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis
por: Jabeen, Kauser, et al.
Publicado: (2021)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

Reply: Transitioning endothelial cells contribute to pulmonary fibrosis
por: Wu, Xiuju, et al.
Publicado: (2023)

Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
por: Mastorino, Luca, et al.
Publicado: (2022)

Monkeypox in the UK: arguments for a broader case definition
por: Pan, Daniel, et al.
Publicado: (2022)

The monkeypox case definition in the UK is broad – Authors' reply
por: Pan, Daniel, et al.
Publicado: (2022)

Self-management interventions for people with pulmonary fibrosis: a scoping review
por: Lee, Joanna Y.T., et al.
Publicado: (2023)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell–based Therapy
por: Wang, Zi-Hao, et al.
Publicado: (2023)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Peripheral Blood Telomere Attrition in Persons at Risk for Familial Pulmonary Fibrosis
por: Salisbury, Margaret L., et al.
Publicado: (2022)

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
por: Spek, C. Arnold, et al.
Publicado: (2023)

Long COVID: current definition
por: Fernández-de-las-Peñas, César
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m2bjlr6i1fal0p839b1fv84anv